Treatment satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a real-life setting by Gohil, Rishma et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.2147/PPA.S105536
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Gohil, R., Crosby-Nwaobi, R., Forbes, A., Burton, B. J., Hykin, P., & Sivaprasad, S. (2016). Treatment
satisfaction of patients undergoing ranibizumab therapy for neovascular age-related macular degeneration in a
real-life setting. Patient Preference and Adherence, 10, 949-955. 10.2147/PPA.S105536
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
© 2016 Gohil et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Patient Preference and Adherence 2016:10 949–955
Patient Preference and Adherence Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
949
O r i g i n A l  r e s e A r c h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/PPA.S105536
Treatment satisfaction of patients undergoing 
ranibizumab therapy for neovascular age-related 
macular degeneration in a real-life setting
rishma gohil1,2
roxanne crosby-nwaobi1,2
Angus Forbes2
Ben J Burton3
Philip hykin1
sobha sivaprasad1,4
1national institute for health 
research Moorfields Biomedical 
research centre, london, 2Diabetes 
nursing, King’s college london, 
london, 3Ophthalmology Department, 
James Paget University hospital, 
great Yarmouth, 4laser and retinal 
research Unit, King’s college 
hospital, london, UK
Context: Treatment satisfaction with a loading phase of monthly injections for 3 months 
followed by a pro-re-nata regimen of ranibizumab in neovascular age-related macular degen-
eration (nAMD) remains unclear.
Aims: The aim was to evaluate the treatment satisfaction of persons with nAMD treated with 
ranibizumab in a real-life setting.
Settings and design: A cross-sectional study was conducted across three eye clinics within 
the National Health Service in the UK, where treatment is provided free at point of contact.
Materials and methods: A total of 250 patients were selected randomly for the study. Treat-
ment satisfaction was assessed using the Macular Treatment Satisfaction Questionnaire. Data 
were collected on satisfaction of the service provided (Client Service Questionnaire-8) and the 
patients’ demographic and quality of life and treatment history. Factors governing treatment 
questionnaire were determined.
Results: The most important factors that determined the satisfaction were the service provided at 
the clinic (Client Service Questionnaire-8), health-related quality of life (EQ-5D-3L), and duration 
of AMD. Visual acuity changes were rated as less important than one would have expected.
Conclusion: The study result suggested that treatment satisfaction for nAMD was governed 
by the perception of being reviewed and injected regularly over a long period of time than the 
actual change in visual acuity from the treatment.
Keywords: macular treatment satisfaction questionnaire, patient related outcome measure, 
treatment history, quality of life
Introduction
Advanced age-related macular degeneration (AMD) is one of the most common causes 
of visual impairment in the older population.1 If left untreated, the neovascular form 
of advanced AMD (nAMD) results in central retinal scaring and atrophy, resulting 
in severe visual loss. Visual loss in the elderly is associated with functional decline, 
an increased utilization of social and community support services, increased risk of 
falls and depression.2–5
In the last decade, there have been significant advances in the treatment of nAMD. 
Clinical trials on repeated intravitreal injections of inhibitors of vascular endothelial 
growth factor (VEGF) in nAMD show that ~30% of individuals show improved 
visual outcomes and 95% show stabilization of vision.6–8 However, the therapy can be 
demanding, as patients require frequent hospital attendance for their injections. The 
therapy burden on patients and caregivers may moderate the real-life outcomes observed 
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outside of the clinical trial9,10 and factors such as patient 
satisfaction with their care may impact on treatment success.
Patient reported outcome measures (PROMs) are increas-
ingly being used to evaluate patient experience in various 
disease management areas. These outcomes measure the 
impact of a treatment on the quality of life of patients. In 
addition to these measures, there has been a recent emphasis 
on assessing the views of patients on the care they receive 
within the clinical service they attend for their treatment. 
Therefore, there has been a surge in the use of both PROMs 
and patient-reported experience measures11 to better qualify 
the overall satisfaction with a service and treatment.6 Patient 
satisfaction of anti-VEGF therapy for nAMD has not been 
evaluated in a real-life setting to date.
The only available disease-specific instrument for mea-
suring treatment satisfaction is the Macular Disease Treat-
ment Satisfaction Questionnaire (MacTSQ) and it has been 
used in the Inhibit VEGF in Age-related choroidal Neovas-
cularisation (IVAN) trial that investigated the comparative 
effectiveness of two anti-VEGF agents and different treat-
ment regimens for nAMD.6,12,13
Ranibizumab is the first intravitreal anti-VEGF licensed 
for nAMD. Currently, the recommended approach for 
ranibizumab in the National Health Service (NHS) is monthly 
monitoring appointments until stability is reached, followed 
by pro-re-nata dosing based on visual acuity and morpho-
logical outcomes.
The aims of this study were to assess the treatment satis-
faction of patients on ranibizumab therapy for nAMD using 
MacTSQ and evaluate the factors, including PROMs, that 
influence the treatment satisfaction score. This was assessed 
in the context of a caregiver burden study for patients on 
ranibizumab therapy for nAMD.
Ethics
The study was approved by the National Research Ethics 
Service Committee (13/WA/0032) and conducted accord-
ing to the tenets of the Declaration of Helsinki. Written 
informed consent was obtained from all the participants prior 
to completion of the non-incentivized questionnaire.
Methods
study design and patients
This cross-sectional questionnaire-based survey was con-
ducted on 250 patient–caregiver pairs from three public 
ophthalmic treatment centers in the UK (North London, 
South London, and East Anglia).14 The pairs were recruited 
from a convenience sample of patients utilizing these three 
centers for ranibizumab treatment of nAMD. To be eligible 
for ranibizumab therapy, the eye had to have a clinic-based 
visual acuity measurement of 24–73 early treatment diabetic 
retinopathy study (ETDRS) letters due to nAMD, with poten-
tial for improvement as recommended by the National Institute 
for Health and Care Excellence.15 The protocol for treatment 
of nAMD is similar in all the three centers, with clinical audits 
from each center indicating equivalent treatment outcomes. 
All the patients were initiated on a loading phase of monthly 
ranibizumab therapy for 3 months followed by 4–6 weekly 
review and pro-re-nata dosing. In a routine clinic appointment, 
the patients underwent visual acuity tests, a macular scan using 
optical coherence tomography, slit-lamp biomicroscopy, and 
were then injected with ranibizumab if deemed necessary. 
The clinic visit time ranged from 1–4 hours, depending on 
the waiting time for evaluation and treatment.
survey tool
The MacTSQ was developed to provide a means of evalu-
ating satisfaction with therapies for macular disease.12 The 
instrument is based on the Retinopathy Treatment Satisfac-
tion Questionnaire,16 with questions specific to diabetic 
retinopathy being replaced by items important to patients 
with macular disease. The MacTSQ is a tool of 12 questions, 
with response options ranging on a 6-point Likert scale to 
rate level of satisfaction from not at all satisfied to completely 
satisfied, generating a range of possible total scores from 
0 to 72 (Table 1). The MacTSQ provides two subscale scores: 
impact of treatment (range 0–36) and information provision 
and convenience (range 0–36).
In addition, the generic Client Service Questionnaire 
(CSQ-8) was also recorded to evaluate the satisfaction 
with health service. The CSQ-8 score is a unidimensional 
questionnaire that assesses the satisfaction of the service 
provided and does not necessarily measure the outcome of 
treatment. The eight questions are scored from 1 to 4, with 
a total maximum score of 32 (Table 2).17,18
The other factors that were recorded were the demo-
graphic data, duration of AMD, number of appointments, 
number of ranibizumab injections, visual acuity of both 
eyes recorded as better and worse eye, change in visual 
acuity since the commencement of treatment, vision-
related quality of life questionnaires (25-item National Eye 
Institute Visual Function Questionnaire)19 and macular 
disease-specific-related quality of life (MacDQoL).20 The 
health-related quality of life was assessed using EQ-5D-3L 
questionnaires.21 The EQ-5D-3L is a generic measure of 
health-related quality of life; it comprises five items from 
which a single index score can be calculated and anchored 
at 0 (equivalent to death) and 1.0 (“full health”).
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statistical analysis
Descriptive statistics of demographic data and Likert scale 
responses included counts and proportions, means (and 
standard deviations), and medians (and interquartile ranges). 
The primary outcome variable was the mean MacTSQ total 
score of satisfaction. Secondary outcomes included the 
mean subscale scores of MacTSQ and mean CSQ-8 score. 
Correlation matrix between covariates of the MacTSQ score 
were computed to assess candidacy for inclusion into a hier-
archical model to assess the factors that are independently 
associated with MacTSQ score. All statistical analysis was 
completed using SPSS 20.0 (IBM Corporation, Armonk, 
NY, USA).
Results
A total of 273 patients were approached to recruit 250 pairs 
of patients and their caregivers (91.5% response rate). The 
characteristic of the patients are summarized in Table 3.
Treatment satisfaction scores
The mean MacTSQ total score was 52.7±8.9. The mean 
subscale scores of information provision and impact of 
Table 1 Macular Treatment satisfaction Questionnaire (MacTsQ)
1 How satisfied are you with the treatment of your AMD?
2 How bothered are you with the side effects or after effects you experience with the treatment of AMD?
3 How bothered are you by any discomfort or pain of the treatment of your AMD?
4 How well do you feel your treatment of AMD is working?
5 How unpleasant did you find your treatment of AMD?
6 How apprehensive did you feel about your most recent treatment of AMD?
7 How satisfied are you about the costs to you associated with the treatment of your AMD?
8 How satisfied are you with the safety of the treatment of your AMD?
9a Were you given information about your AMD treatment (eg, information about procedures, benefits, and any risks)?
9b Was the information given to you in the way you can take home (eg, in a leaflet)?
9c How satisfied are you with the information provided about the treatment of your AMD?
10 If further treatment is required for your AMD, how satisfied would you be to continue or repeat the treatment?
11 How satisfied are you with the time spent in the clinic on each treatment day?
12 How satisfied are you with the overall duration of the treatment for your AMD?
13 Would you encourage someone else with AMD like yours to have this kind of treatment?
14 Are there any other aspects of the treatment for your AMD, causing satisfaction or dissatisfaction, that have not been covered already?
Abbreviation: AMD, age-related macular degeneration.
Table 2 client service Questionnaire (csQ-8)
Question Responses
1. how would you rate the quality of service 
you received?
4
excellent
3
good
2
Fair
1
Poor
2. Did you get the kind of service you wanted? 1
No, definitely not
2
no, not really
3
Yes, generally
4
Yes, definitely
3. To what extent has our program met your 
needs?
4
Almost all of my 
needs have been met
3
Most of my needs 
have been met
2
Only a few of my 
needs have been met
1
none of my needs 
have been met
4. if a friend were in need of similar help, would 
you recommend our program to him or her?
1
No, definitely not
2
no, not really
3
Yes, generally
4
Yes, definitely
5. How satisfied are you with the amount of 
help you have received?
1
Quite dissatisfied
2
indifferent or 
mildly dissatisfied
3
Mostly satisfied
4
Very satisfied
6. have the services you received helped you 
to deal more effectively with your problems?
4
Yes, they helped a 
great deal
3
Yes, they helped 
somewhat
2
no, they really did 
not help
1
no, they seemed to 
make things worse
7. In an overall, general sense, how satisfied are 
you with the service you have received?
4
Very satisfied
3
Mostly satisfied
2
indifferent or mildly 
dissatisfied
1
Quite dissatisfied
8. if you were to seek help again, would you 
come back to our program?
1
No, definitely not
2
no, i don’t think so
3
Yes, i think so
4
Yes, definitely
Any comments or suggestions?  
Note: Questions 2, 4, 5, and 8 are reverse scored.
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treatment were 27.6±3.9 and 25.0±6.5 respectively. The mean 
total CSQ-8 score was 24.8±2.0. Correlation of MacTSQ with 
other variables is shown in Table 4.
The hierarchal model in Table 5 explains ~15% of the 
observed variance in the MacTSQ score with satisfaction 
with the health service, duration of AMD, and health-related 
quality of life being the only significant determinants within 
the model.
Discussion
To our knowledge, this is the first study to evaluate patient 
satisfaction for outcomes in nAMD treated with anti-VEGF 
therapy in a real-life setting. One of the main findings is that 
traditional clinical outcomes of visual acuity improvement 
and stabilization are not clearly prioritized by patients over 
outcomes related to the process of care.
The most important factors that determined the satisfac-
tion were the service provided at the clinic (CSQ-8), health-
related quality of life (EQ-5D-3L), and duration of AMD.
Visual acuity changes were rated as less important than 
one would have expected. The perception of being reviewed 
and injected regularly over a long period of time seems to 
influence the MacTSQ score more positively than the actual 
change in visual acuity from the treatment.
The mean change in visual acuity from baseline 
was 4.9 letters, which is similar to other real-life visual 
outcomes with ranibizumab.9,10 Both the change in visual 
acuity and the visual acuity on the date of interview did 
not determine the satisfaction score. One may attribute this 
to the fact that ~50% of patients had good visual acuity of 
at least 74 ETDRS letters in the better-seeing eye in this 
study. However, the MacTSQ scores were also evaluated in 
the REPAIR study that evaluated ranibizumab for myopic 
choroidal neovascularization.22 Despite a younger popula-
tion (mean 55 years old) and less number of injections, the 
MacTSQ score did not correlate with visual acuity change 
Table 3 Patient characteristics
Variable n (%)
Demographic
Age in years, mean age ± sD 79.6±8.8
80 years 138 (55.2)
70–80 81 (32.4)
60–69 24 (9.6)
50–59 7 (2.8)
sex 
Male 64 (25.6)
Female 186 (74.4)
living alone
Yes 90 (36)
no 160 (64)
Marital status
single 11 (4.4)
Married/partner 134 (53.6)
separated/divorced 19 (7.6)
Widowed 86 (34.4)
employment status
employed 14 (5.6)
Unemployed 1 (0.4)
retired 235 (94.0)
Visual acuity
Visual acuity in better eye (eTDrs letters)
74 122 (48.8)
54–73 93 (37.2)
54 35 (14.0)
Visual acuity in worse eye (eTDrs letters)
74 27 (10.8)
54–73 69 (27.6)
37–53 31 (12.4)
37 123 (49.2)
NEI-VFQ-25 total composite and score profile
Mean total, mean ± sD 56.1±22.0
90 11 (4.8)
80–89 30 (13.1)
70–79 33 (14.4)
60–69 22 (9.6)
50–59 29 (12.7)
40–49 30 (13.1)
30–39 32 (14.0)
30 42 (18.3)
Mean duration AMD (months), mean ± sD 36.2±20.7
care, treatment, and therapy outcome
number of appointments
3 20 (8.1)
4–6 23 (9.3)
7–9 33 (13.4)
10 132 (53.4)
number of ranibizumab injections
3 37 (15.0)
4–6 45 (18.2)
7–9 33 (13.4)
10 132 (53.4)
VA  change post-treatment, mean ± sD
Overall 4.9±21
(Continued)
Table 3 (Continued)
Variable n (%)
health-related quality of life, mean ± sD 
eQ-5D-3l
index 0.68±0.22
VAs 64.6±15.0
MacDQol
Total −0.6591.8
Note: Data shown as mean ± sD and n (%).
Abbreviations: AMD, age-related macular degeneration; MacDQol, macular 
disease-specific-related quality of life; SD, standard deviation; VA, visual acuity; VAS, 
visual analog score; nei-VFQ-25, 25-item national eye institute Visual Function 
Questionnaire; eTDrs, early treatment diabetic retinopathy study.
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or baseline visual acuity of the study eye. The scores also 
did not vary between the study eye being the better or the 
worse seeing eye. Therefore, the results of this study further 
substantiate the fact that the MacTSQ score is independent 
of visual acuity scores.
The mean MacTSQ score on patients with AMD treated 
with ranibizumab in real life in this study was 52.7 compared 
with the median of 66 in the randomized clinical trial IVAN, 
which compared ranibizumab and bevacizumab for AMD, 
indicating that satisfaction among patients in real life is lower 
than for those in clinical trials. This may be explained by the 
fact that patients generally find participation in retinal clinical 
trials to be a positive experience.23 The services provided 
in clinical trials are more patient-centered and patients are 
more involved in the decision-making process. Moreover, 
exclusion criteria in clinical trials usually result in a healthier 
cohort being recruited.
This study also showed that health-related quality of life 
is a factor that determined patient satisfaction. The mean 
EQ-5D-3L score in this study was 0.68 compared to 0.85 
in the IVAN trial and this difference may also explain the 
higher satisfaction score in IVAN trial compared to this 
study. However, the mean EQ-5D-3L visual analog score 
and the utility score in this study were within the range of 
Table 4 correlation matrix of continuous variables
1
MacTSQ 
(total)
2
CSQ-8
3
Age
4
Duration 
AMD
5
VA 
change
6
Number of 
injections
7
Number of 
appointments
8
VFQ 
(total)
9
MacDQoL
10
EQ-5D-3L 
VAS
11
EQ-5D-3L 
Index
1 −0.27** 0.08 0.17** 0.09 0.14* 0.21** 0.12 0.03 0.10 0.25**
2 −0.27** −0.04 −0.07 −0.20** −0.06 −0.09 −0.16* 0.07 −0.24** −0.19**
3 0.08 −0.04 0.25** −0.24** 0.09 0.20** −0.01 0.03 −0.04 −0.02
4 0.17** −0.07 0.25** 0.01 0.69** 0.61** −0.02 0.16** −0.07 0.07
5 0.09 −0.20** −0.24** 0.01 0.08 0.04 0.00 −0.19** 0.22** 0.02
6 0.14* −0.06 0.09 0.69** 0.08 0.59** −0.03 0.10 −0.05 0.04
7 0.21** −0.09 0.20** 0.61** 0.04 0.59** −0.10 0.13* 0.08 0.09
8 0.12 −0.16* −0.01 −0.02 0.00 −0.03 −0.10 −0.27** 0.12 0.36**
9 0.03 0.07 0.03 0.16** −0.19** 0.10 0.13* −0.27** −0.26** −0.15*
10 0.10 −0.24** −0.04 −0.07 0.22** −0.05 0.08 0.12 −0.26** 0.32**
11 0.25** −0.19** −0.02 0.07 0.02 0.04 0.09 0.36** −0.15* 0.32**
Notes: *Correlation is significant at the 0.05 level (two-tailed). **Correlation is significant at the 0.01 level (two-tailed).
Abbreviations: AMD, age-related macular degeneration; CSQ-8, Client Service Questionnaire; MacDQoL, macular disease-specific-related quality of life; MacTSQ, Macular 
Treatment satisfaction Questionnaire; VAs, visual analog score.
Table 5 hierarchical regression models predicting treatment satisfaction (MacTsQ) in patients with AMD treated with intravitreal 
ranibizumab
Model Variable statistics 
full model
Model statistics
Stand β Sig Block ∆R2 Adj R2 R2 change F-change P-value
Demographics
carer sex 0.085 0.212
Age −0.053 0.434
living alone −0.035 0.612 1 0.012 −0.002 0.012 0.87 0.466
Vision
VA better eye pre-therapy 0.039 0.573
nei-VFQ 0.074 0.272
Duration AMD 0.211 0.002 2 0.059 0.033 0.048 3.666 0.013
care and treatment
no injections 0.064 0.475
VA change 0.078 0.267
care satisfaction (csQ-8) −0.228 0.001 3 0.122 0.085 0.063 5.117 0.002
health-related Qol
eQ-5D-3l (index) 0.192 0.005 4 0.154 0.114 0.032 7.990 0.005
Abbreviations: AMD, age-related macular degeneration; csQ-8, client service Questionnaire; MacTsQ, Macular Treatment satisfaction Questionnaire; VA, visual acuity; 
NEI-VFQ-25, 25-item National Eye Institute Visual Function Questionnaire; QoL, quality of life; Sig, significance.
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previous cross-sectional studies on nAMD (range 0.64–0.89 
and 64–82, respectively) providing further evidence of the 
generalizability of this study.24,25
Another finding of this study was that there was no 
correlation between either 25-item National Eye Institute 
Visual Function Questionnaire or MacDQoL with treatment 
satisfaction. Therefore, this study further highlights that 
PROMs and patient-reported experience measures may not 
always correlate and therefore both these outcomes should 
be measured together to fully evaluate patients’ views of 
their symptoms, health-related quality of life, and satisfac-
tion with treatment.
A major strength of this study is that this is the first study 
that has evaluated treatment satisfaction with anti-VEGF for 
AMD in real life. The study also prospectively evaluated all 
potential factors that could influence patient satisfaction with 
this therapy in a representative clinic catering to a diverse 
population. Additionally, an independent interviewer rather 
than a health care provider conducted the survey to reduce 
the response bias.
The study limitations included its cross-sectional design. 
We were also not able to evaluate the input of other medical 
conditions and relied on EQ-5D-3L. However, drug apprais-
als on this condition are also reliant on EQ-5D-3L.
A final area of limitation could be a selection bias. The 
sample was one of convenience with ambulant clients who 
attended the hospital visit with an unpaid carer and had 
volunteered for the study. It is possible that patients who 
are generally not overly burdened by their condition could 
have been more likely to volunteer, or the responses may 
have been in a more positive direction than for the broader 
community of people with nAMD. However, the effect of 
this would be to underplay (rather than overplay) the level 
of satisfaction.
In summary, this study provides an insight into treat-
ment satisfaction of patients receiving ranibizumab therapy 
for nAMD and the factors that contribute to the burden. 
Future research in this area needs to validate these findings 
in different health systems in prospective comparative and 
longitudinal studies.
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